Suppr超能文献

累及上矢状窦的脑膜瘤:初次及复发病例经机器人放射外科治疗后的长期疗效

Meningioma involving the superior sagittal sinus: long-term outcome after robotic radiosurgery in primary and recurrent situation.

作者信息

Schmutzer Michael, Skrap Benjamin, Thorsteinsdottir Jun, Fürweger Christoph, Muacevic Alexander, Schichor Christian

机构信息

Department of Neurosurgery, University Hospital, Ludwig-Maximilians-University (LMU), Munich, Germany.

European Radiosurgery Centre, Munich, Germany.

出版信息

Front Oncol. 2023 Jul 11;13:1206059. doi: 10.3389/fonc.2023.1206059. eCollection 2023.

Abstract

OBJECTIVE

Treatment for meningiomas involving the superior sagittal sinus (SSS) is challenging and proved to be associated with higher risks compared to other brain locations. Therapeutical strategies may be either microsurgical (sub-)total resection or adjuvant radiation, or a combination of both. Thrombosis or SSS occlusion following resection or radiosurgery needs to be further elucidated to assess whether single or combined treatment is superior. We here present tumor control and side effect data of robotic radiosurgery (RRS) in combination with or without microsurgery.

METHODS

From our prospective database, we identified 137 patients with WHO grade I meningioma involving the SSS consecutively treated between 2005 and 2020. Treatment decisions were interdisciplinary. Patients underwent RRS as initial/solitary treatment (group 1), as adjuvant treatment after subtotal resection (group 2), or due to recurrent tumor growth after preceding microsurgery (group 3). Positive tumor response was assessed by MRI and defined as reduction of more than 50% of volume. Study endpoints were time to recurrence (TTR), time to RRS, risk factors for decreased survival, and side effects. Overall and specific recurrence rates for treatment groups were analyzed. Side effect data included therapy-related morbidity during follow-up (FU).

RESULTS

A total of 137 patients (median age, 58.3 years) with SSS meningiomas WHO grade I were analyzed: 51 patients (37.2%) in group 1, 15 patients (11.0%) in group 2, and 71 patients (51.8%) in group 3. Positive MR (morphological response) to therapy was achieved in 50 patients (36.4%), no response was observed in 25 patients (18.2%), and radiological tumor progression was detected in 8 patients (5.8%). Overall 5-year probability of tumor recurrence was 15.8% (median TTR, 41.6 months). Five-year probabilities of recurrence were 0%, 8.3.%, and 21.5% for groups 1-3 ( = 0.06). In multivariate analysis, tumor volume was significantly associated with extent of SSS occlusion ( = 0.026) and sex ( = 0.011). Tumor volume significantly correlated with TTR ( = 0.0046). Acute sinus venous thrombosis or venous congestion-associated bleedings did not occur in any of the groups.

CONCLUSION

RRS for grade I meningiomas with SSS involvement represents a good option as first-line treatment, occasionally also in recurrent and adjuvant scenarios as part of a multimodal treatment strategy.

摘要

目的

与其他脑区相比,涉及上矢状窦(SSS)的脑膜瘤治疗具有挑战性,且风险更高。治疗策略可以是显微手术(次)全切除或辅助放疗,或两者结合。切除或放射外科手术后的血栓形成或SSS闭塞情况需要进一步阐明,以评估单一治疗或联合治疗哪种更具优势。我们在此展示机器人放射外科手术(RRS)联合或不联合显微手术的肿瘤控制及副作用数据。

方法

从我们的前瞻性数据库中,我们确定了137例2005年至2020年间连续接受治疗的WHO I级涉及SSS的脑膜瘤患者。治疗决策是跨学科的。患者接受RRS作为初始/单一治疗(第1组)、次全切除后的辅助治疗(第2组)或先前显微手术后肿瘤复发生长的治疗(第3组)。通过MRI评估肿瘤阳性反应,定义为体积缩小超过50%。研究终点为复发时间(TTR)、接受RRS的时间、生存降低的风险因素及副作用。分析治疗组的总体和特定复发率。副作用数据包括随访(FU)期间与治疗相关的发病率。

结果

共分析了137例WHO I级SSS脑膜瘤患者(中位年龄58.3岁):第1组51例(37.2%),第2组15例(11.0%),第3组71例(51.8%)。50例患者(36.4%)治疗后获得阳性MR(形态学反应),25例患者(18.2%)无反应,8例患者(5.8%)检测到放射学肿瘤进展。总体5年肿瘤复发概率为15.8%(中位TTR为41.6个月)。第1 - 3组的5年复发概率分别为0%、8.3%和21.5%(P = 0.06)。多变量分析中,肿瘤体积与SSS闭塞程度(P = 0.026)和性别(P = 0.011)显著相关。肿瘤体积与TTR显著相关(P = 0.0046)。所有组均未发生急性窦静脉血栓形成或静脉充血相关出血。

结论

对于累及SSS的I级脑膜瘤,RRS作为一线治疗是一个不错的选择,偶尔也可作为多模式治疗策略的一部分用于复发和辅助治疗情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e27/10367096/1231600e7b30/fonc-13-1206059-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验